[1] |
ABU-HILAL M, TAWAKER J. Portal hypertension secondary to myelofibrosis with myeloid metaplasia: A study of 13 cases[J]. World J Gastroenterol, 2009, 15(25): 3128-3133. DOI: 10.3748/wjg.15.3128.
|
[2] |
POTTHOFF A, ATTIA D, PISCHKE S, et al. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms[J]. Liver Int, 2015, 35(8): 2042-2049. DOI: 10.1111/liv.12816.
|
[3] |
SOKOLOVA M, TSVETAEVA N, SUKHANOVA G, et al. Ph-negative chronic myeloproliferative neoplasm (primary myelofibrosis) - as one of the reasons of the budd-Chiari syndrome[J]. Mediterr J Hematol Infect Dis, 2012, 4(1): e2012047. DOI: 10.4084/MJHID.2012.047.
|
[4] |
CERVANTES F, BAROSI G, HERNÁNDEZ-BOLUDA JC, et al. Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: Presenting features, evolution and survival[J]. Eur J Haematol, 2001, 66(5): 324-327. DOI: 10.1034/j.1600-0609.2001.066005324.x.
|
[5] |
QI X, JIA J, BAI M, et al. Portal hypertension complicating myelofibrosis in a patient without portal or hepatic vein thrombosis[J]. Ann Gastroenterol, 2014, 27(2): 188.
|
[6] |
VAHABZADEH B, CRIPPIN JS. Image of the month. Portal hypertension as a result of extramedullary hematopoiesis caused by idiopathic myelofibrosis[J]. Clin Gastroenterol Hepatol, 2008, 6(4): e22. DOI: 10.1016/j.cgh.2008.01.008.
|
[7] |
REILLY CR, BABUSHOK DV, MARTIN K, et al. Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension[J]. Am J Hematol, 2017, 92(9): 909-914. DOI: 10.1002/ajh.24798.
|
[8] |
DOKI N, IRISAWA H, TAKADA S, et al. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis[J]. Intern Med, 2007, 46(4): 187-190. DOI: 10.2169/internalmedicine.46.1768.
|
[9] |
ALVAREZ-LARRÁN A, ABRALDES JG, CERVANTES F, et al. Portal hypertension secondary to myelofibrosis: A study of three cases[J]. Am J Gastroenterol, 2005, 100(10): 2355-2358. DOI: 10.1111/j.1572-0241.2005.50374.x.
|
[10] |
WIEST R, STRAUCH U, WAGNER H, et al. A patient with myelofibrosis complicated by refractory ascites and portal hypertension: To tips or not to tips? A case report with discussion of the mechanism of ascites formation[J]. Scand J Gastroenterol, 2004, 39(4): 389-394. DOI: 10.1080/00365520310007521.
|
[11] |
BĚLOHLÁVEK J, SCHWARZ J, JIRÁSEK A, et al. Idiopathic myelofibrosis complicated by portal hypertension treated with a transjugular intrahepatic portosystemic shunt (TIPS)[J]. Wien Klin Wochenschr, 2001, 113(5-6): 208-211.
|
[12] |
HOW J, ZHOU A, OH ST. Splanchnic vein thrombosis in myeloproliferative neoplasms: Pathophysiology and molecular mechanisms of disease[J]. Ther Adv Hematol, 2017, 8(3): 107-118. DOI: 10.1177/2040620716680333.
|
[13] |
TAN HK, LEOW WQ, CHANG PE. Ruxolitinib for the treatment of portal hypertension in a patient with primary myelofibrosis[J]. Gastroenterology, 2019, 157(5): e26-e27. DOI: 10.1053/j.gastro.2016.08.059.
|
[14] |
PANDA A, CHANDRASHEKHARA SH, NAMBIRAJAN A, et al. Idiopathic myelofibrosis with disseminated hepatosplenic, mesenteric, renal and pulmonary extramedullary haematopoeisis, portal hypertension and tuberculosis: Initial presentation and 2 years follow-up[J]. BMJ Case Rep, 2016, 2016. DOI: 10.1136/bcr-2016-217854.
|
[15] |
DURCHSCHEIN F, KRONES E, EHERER AJ, et al. Sclerotherapy-associated esophageal hematoma in a patient with myelofibrosis and portal hypertension[J]. Endoscopy, 2015, 47(Suppl 1)UCTN: e20-e21. DOI: 10.1055/s-0034-1390725.
|
[16] |
TOKAI K, MIYATANI H, YOSHIDA Y, et al. Multiple esophageal variceal ruptures with massive ascites due to myelofibrosis-induced portal hypertension[J]. World J Gastroenterol, 2012, 18(28): 3770-3774. DOI: 10.3748/wjg.v18.i28.3770.
|
[17] |
de FRANCHIS R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
|
[18] |
BARBUI T, THIELE J, GISSLINGER H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion[J]. Blood Cancer J, 2018, 8(2);15. DOI: 10.1038/s41408-018-0054-y.
|
[19] |
RUMI E, CAZZOLA M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms[J]. Blood, 2017, 129(6): 680-692. DOI: 10.1182/blood-2016-10-695957.
|
[20] |
TEFFERI A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management[J]. Am J Hematol, 2018, 93(12): 1551-1560. DOI: 10.1002/ajh.25230.
|
[21] |
SILVERSTEIN MN, WOLLAEGER EE, BAGGENSTOSS AH. Gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia[J]. Arch Intern Med, 1973, 131(4): 532-537. DOI: 10.1001/archinte.1973.00320100060007
|
[22] |
LIGUMSKI M, POLLIACK A, BENBASSAT J. Nature and incidence of liver involvement in agnogenic myeloid metaplasia[J]. Scand J Haematol, 1978, 21(2): 81-93. DOI: 10.1111/j.1600-0609.1978.tb02497.x.
|
[23] |
VANNUCCHI AM. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia[J]. Intern Emerg Med, 2010, 5(3): 177-184. DOI: 10.1007/s11739-009-0319-3.
|
[24] |
FUJIYAMA S, SAITOH S, KAWAMURA Y, et al. Portal vein thrombosis in liver cirrhosis: Incidence, management, and outcome[J]. BMC Gastroenterol, 2017, 17(1): 112. DOI: 10.1186/s12876-017-0668-8.
|
[25] |
QI X, HAN G, FAN D. Management of portal vein thrombosis in liver cirrhosis[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(7): 435-446. DOI: 10.1038/nrgastro.2014.36.
|
[26] |
DELEVE LD, VALLA DC, GARCIA-TSAO G. Vascular disorders of the liver[J]. Hepatology, 2009, 49(5): 1729-1764. DOI: 10.1002/hep.22772.
|
[27] |
SONG ZQ, ZHOU LY. A clinical analysis of six cases of portal hypertension secondary to primary myelofibrosis and review of literatures[J]. Chin J Intern Med, 2010, 49(10): 845-847. DOI: 10.3760/cma.j.issn.0578-1426.2010.10.009.
宋志强, 周丽雅. 原发性骨髓纤维化继发门脉高压症六例分析并文献复习[J]. 中华内科杂志, 2010, 49(10): 845-847. DOI: 10.3760/cma.j.issn.0578-1426.2010.10.009.
|
[28] |
WANG X, HE TT, ZHANG N, et al. Clinical characteristics of 12 patients with primary myelofibrosis and liver cirrhosis[J]. J Clin Hepatol, 2020, 36(11): 2524-2526. DOI: 10.3969/j.issn.1001-5256.2020.11.025.
王宣, 何婷婷, 张宁, 等. 12例原发性骨髓纤维化合并肝硬化患者的临床特征分析[J]. 临床肝胆病杂志, 2020, 36(11): 2524-2526. DOI: 10.3969/j.issn.1001-5256.2020.11.025.
|